Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? - PubMed
14 hours ago
- #cost-effectiveness
- #biosimilars
- #Crohn's disease
- The study evaluates the cost-effectiveness of treatment sequences including biosimilar ustekinumab (bsUST) for moderate-to-severe Crohn's disease in Spain.
- A Markov model was used to simulate health states and treatment changes over a lifetime horizon, incorporating efficacy data from various treatments.
- Sequence 2 (bsUST, bsADA, UPA, RIS, Q) was identified as the only cost-effective strategy at a willingness-to-pay threshold of €27,000/QALY, with an ICER of €8672.6/QALY.
- Positioning bsUST as a first-line treatment is cost-effective and efficient from the Spanish NHS perspective, improving patient access due to lower drug costs.
- Probabilistic sensitivity analysis confirmed Sequence 2 as the cost-effective option in 98.03% of simulations.